DEVON ISAAC: Open Payments
NPI 1124806963 · ABINGDON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$471 in 17 payments from 9 companies in 2025. Trend: 2023 $87 · 2024 $736 · 2025 $471
Food & beverage: $471
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $146 |
| Daiichi Sankyo Inc. | 3 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Janssen Biotech, Inc. | 1 | $44 |
| Caris MPI, Inc. | 2 | $37 |
| Gamida Cell Inc. | 1 | $27 |
| Syndax Pharmaceuticals, Inc. | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| TerSera Therapeutics LLC | 1 | $22 |
Products named: Enhertu, FRUZAQLA, TECVAYLI, MI CANCER SEEK, Vanflyta, OMISIRGE, KEYTRUDA, Zoladex.
Industry payments across MD — which companies pay providers there.
